Search Results - H. Hebart

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    P646: EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH RITUXIMAB (VENR) IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL... by I. Schwaner, H. Hebart, C. Losem, T. Wolff, K. Famulla, J. Huelsenbeck, B. Schmidt, T. Nösslinger, D. Rossi

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY by I. Schwaner, H. Hebart, C. Losem, T. Wolff, K. Famulla, J. Huelsenbeck, B. Schmidt, T. Nösslinger, D. Rossi

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA by F. Stegelmann, E. Jahn, S. Koschmieder, F. Heidel, A. Hochhaus, H. Hebart, S. Isfort, A. Reiter, M. Bangerter, C. F. Waller, D. Wolleschak, C. Scheid, J. Göthert, P. Schafhausen, T. Kindler, M. P. Radsak, N. Gattermann, R. Möhle, N. von Bubnoff, A. Schrade, T. Brümmendorf, H. Döhner, M. Griesshammer, K. Döhner

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: